On May 2, 2023, Elanco Animal Health announced that the U.S. Department of Agriculture had provided a conditional license for the first Canine Parvovirus Monoclonal Antibody. This was the first and only approved therapeutic solution proven to treat canine parvovirus ﾗ one of the most contagious and deadly viruses a dog can contract with a 91% mortality rate if not treated with supportive carei. The treatment is the first monoclonal antibody for Elanco, an important innovation platform for the company.